Watch on earnings: Quarterly operating cash burn rate and total cash/equivalents balance (runway calculation), Number of active platform licenses and new partnership announcements with deal terms, Partner pipeline progression: count of programs in Phase 1/2/3 clinical trials using OmniAb technology.
One Sentence Summary:
OmniAb: the story is balanced — new platform licensing deals with pharmaceutical partners (deal size, partner quality, therapeutic area).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.